Susceptibility of bacterial isolates to cefepime in comparison to other broad spectrum antimicrobial agents at a tertiary care center in Lebanon

Journal Medical Libanais

Volumn 49, Issue 1, 2001, Pages 13-17

  Kanj, Souha S ^a   Chedid, Marwan ^a   Araj, George F ^a  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIINFECTIVE AGENT; AZTREONAM; CEFALOTIN; CEFAMANDOLE; CEFEPIME; CEFIXIME; CEFOXITIN; CEFTAZIDIME; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; ERYTHROMYCIN; GENTAMICIN; IMIPENEM; NORFLOXACIN; OXACILLIN; PEFLOXACIN; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; SULFAMETHOXAZOLE; TEICOPLANIN; TOBRAMYCIN; VANCOMYCIN;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; ENTEROBACTERIACEAE; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; LEBANON; STREPTOCOCCUS; STREPTOCOCCUS PNEUMONIAE;

CEPHALOSPORIN RESISTANCE; CEPHALOSPORINS; ESCHERICHIA COLI; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HUMANS; KLEBSIELLA; MICROBIAL SENSITIVITY TESTS; STAPHYLOCOCCUS;

EID: 0035726944     PISSN: 00239852     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. The cephalosporins
2. The cephalosporins
3. Impact of changing pathogens and antimicrobial susceptibility patterns in the treatment of serious infections in hospitalized patients
4. Antibiotic susceptibility among aerobic gram-negative bacilli in intensive care units in 5 European countries
5. Cefepime: The next generation
6. Nosocomial acquisition of multi-resistant Acinetobacter baumannii: Risk factors and prognosis
7. Cefepime: A review of its antibacterial activity. Pharmacokinetic properties and therapeutic use
8. In vitro activity of fourth generation cephalosporins against Enterobacteriacae producing extended spectrum β-lactamases
9. Antimicrobial activity of cefepime tested against Bush group 1 β-lactamase-producing strains resistant to ceftazidime
10. Comparative activity of eight antimicrobial agents against clinical bacterial isolates from the United States, measured by two methods
11. Efficacy of cefepime in the treatment of infections due to multiply resistant Enterobacter species
12. Antimicrobial resistance in Lebanon
13. The role of fourth-generation cephalosporins in the treatment of infections caused by penicillin-resistant streptococci
14. Drug resistant Streptococcus pneumoniae in Lebanon: Implications for presumptive therapy
15. Comparaison of cefpirome, cefepime, and cefclidine binding affinities for penicillin binding proteins in Escherichia coli K-12 and Pseudomonas aeruginosa SC 8329
16. Fourth generation cephalosporins: A review of in vitro activity, pharmacokinetics, pharmacodynamics and clinical utility
17. Antimicrobial activity and spectrum investigation of eight broad spectrum β-lactams drugs: A 1997 surveillance trial in 102 medical centers in the United States
18. Efficacy of cefepime and amikacin in the empiric treatment of febrile neutropenic children with cancer
19. Open randomized study of cefepime versus piperacillin-gentamicin for treatment of febrile neutropenic cancer patients
20. Cefepime/ amikacin versus ceftazidime/amikacin as empirical therapy for febrile episodes in neutropenic patients: A comparative study
21. A comparative study of cefepime versus ceftazidime as empiric therapy of febrile episodes in neutropenic patients
22. Cefepime as empirical monotherapy in febrile patients with hematological malignancies and neutropenia: A randomized, single-center phase II trial
23. Cefepime
24. Treatment of urinary tract infections: Selecting an appropriate broad-spectrum antibiotic for nosocomial infection
25. Cefepime vs. ceftazidime treatment of pyelonephritis: A European, randomized, controlled study of 300 pediatric cases
26. Cefepime versus ceftriaxone for empiric treatment of hospitalized patients with community-acquired pneumonia
27. Respiratory tract pathogens isolated from patients hospitalized with suspected pneumonia: Frequency of occurrence and antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 1997)
28. Cefepime versus ceftriaxone for empiric treatment of hospitalized patients with community-acquired pneumonia
29. A randomized double-blind clinical trial comparing cefepime plus metronidazole with imipenem-cilastatin in the treatment of complicated intraabdominal infections
30. Current and future management of serious skin and skin-structure infections
31. Evaluation of cefepime alone and in combination with vancomycin against penicillin-resistant pneumococci in the rabbit meningitis model and in vitro
32. Diffusion of 3-quaternary ammonium cephem antibiotics into cerebrospinal fluid of patients with bacterial meningitis
33. Therapeutic studies of cefepime (BMY 28142) in murine meningitis and pharmacokinetics in neonatal rats
34. Safety of cefepime: A new extended spectrum parenteral cephalosporins